Servier Pharmaceuticals

Servier Pharmaceuticals is the U.S. arm of Servier Group, a privately held international drug company governed by an independent non-profit foundation. Based in the Seaport, the U.S. business is a leader in oncology and is building up its neurology business, with an emphasis on rare diseases and patient populations with unmet needs. The company says smaller patient populations do not deter it, and its oncology portfolio includes first-in-class and best-in-class precision therapies.

Foundation governance means the company is free of influence from outside investors, which it says allows a long-term view instead of short-term financial targets. Servier Group reinvests 25 percent of its revenue, excluding generics, into research and development each year. The U.S. team pairs in-house research with a network of partners, and the company supports patients and families beyond the clinic, including children living with pediatric low-grade glioma.

What to Know

• Servier Group operates in more than 130 countries.
• The company lists its values as daring to innovate, caring deeply, committing to success and growing through shared efforts.
• The U.S. business describes itself as pairing a global company’s resources with the entrepreneurial spirit of a biotech.
• Servier publishes a Corporate Sustainability Report on its community commitments.